Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05818085 · ClinicalTrials.gov registry record · Phase 2
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
A Phase 2 study, sponsored by Atom Therapeutics Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT05818085 is a Phase 2 study that has completed, run by Atom Therapeutics Co.. The registered enrollment target is 300 participants.
The verdict
NCT05818085, a Phase 2 study, has completed, sponsored by Atom Therapeutics Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
Interventions
- OTHER Placebo
- DRUG Allopurinol
- DRUG ABP-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-08-11 |
| Est. Completion | 2025-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05818085
The ClinicalTrials.gov registry entry for NCT05818085 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05818085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05818085 about?
NCT05818085 is a clinical study titled "Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout". This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) o...
What is the current status of trial NCT05818085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2023-08-11. Estimated completion is 2025-03-30.
What interventions are being tested in trial NCT05818085?
The interventions under investigation include: Placebo (OTHER), Allopurinol (DRUG), ABP-671 (DRUG).
Who is sponsoring clinical trial NCT05818085?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.